{"id":13017,"date":"2021-07-29T17:42:36","date_gmt":"2021-07-29T12:12:36","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=13017"},"modified":"2021-08-31T14:43:42","modified_gmt":"2021-08-31T09:13:42","slug":"recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier","title":{"rendered":"Amgen acquires Teneobio for $2.5B; Signifier scores $35M; Biogen-Ionis\u2019 drug meets a goal; AbbVie hits go on $1B re-upped Calico deal"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fbf6de991d5\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fbf6de991d5\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier\/#Teneobio_and_its_next-gen_cancer_work_acquired_by_Amgen\" >Teneobio and its next-gen cancer work acquired by Amgen&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier\/#Signifier_raises_USD_35_Million_to_accelerate_commercialization_of_eXciteOSA_therapy\" >Signifier raises USD 35 Million to accelerate commercialization of eXciteOSA therapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier\/#Biogen-Ionis_experimental_drug_meets_primary_goal_in_Alzheimers_trial\" >Biogen-Ionis\u2019 experimental drug meets primary goal in Alzheimer\u2019s trial<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier\/#AbbVie_hits_go_on_USD_1_Billion_re-upped_Calico_deal_as_Googles_life_science_spin-out_continues_I-O_Neuropush\" >AbbVie hits go on USD 1 Billion re-upped Calico deal as Google\u2019s life science spin-out continues I-O, Neuropush<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Teneobio_and_its_next-gen_cancer_work_acquired_by_Amgen\"><\/span><strong>Teneobio and its next-gen cancer work acquired by Amgen&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Amgen has penned a major new buyout deal to boost its oncology pipeline further. The biopharma is putting USD 900 million down upfront, with USD 1.6 billion in biobucks on the table to buy Teneobio and its suite of bispecific and multispecific antibody technologies focused on cancer and other disease targets.<\/p>\n\n\n\n<p>The deal adds TNB-585, a phase 1 bispecific T cell-engager zeroed in at <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/castrate-resistant-prostate-cancer-market\">metastatic castrate-resistant prostate cancer (mCRPC)<\/a><\/strong>, and several preclinical oncology pipeline assets with the potential for near-term IND filings.&nbsp;<\/p>\n\n\n\n<p>TNB-585 complements Amgen&#8217;s existing <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-market\">prostate cancer<\/a><\/strong> portfolio, including acapatamab (formerly AMG 160), a half-life extended, PSMA-targeted BiTE; and AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, which is both in phase 1.<\/p>\n\n\n\n<p>The acquisition of Teneobio will bolster their ability to develop innovative medicines to treat patients with serious illnesses and to bring to market best-in-class products, particularly concerning multispecific and bispecific medicines directed against targets in a broad range of diseases across their core therapeutic areas, as said by David M. Reese, M.D., executive vice president of research and development at Amgen.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signifier_raises_USD_35_Million_to_accelerate_commercialization_of_eXciteOSA_therapy\"><\/span><strong>Signifier raises USD 35 Million to accelerate commercialization of eXciteOSA therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Signifier Medical Technologies now has about 35 million other things to add to its mission to build devices to enhance <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/circadian-rhythm-sleep-disorders-market\">sleep-disordered<\/a><\/strong> breathing.<\/p>\n\n\n\n<p>The London-based company recently closed its Series D funding round, which brought in USD 35 million from lead investors Segulah Medical Acceleration, Angelus Venture Fund I, Pioneer Healthcare Partners, and Alan Howard, the co-founder of European hedge fund platform Brevan Howard Asset Management.<\/p>\n\n\n\n<p>Following close behind the FDA\u2019s nod of Signifier\u2019s flagship device for treating mild cases of sleep apnea and excessive snoring, the financing will mainly be utilized to back the commercialization of the eXciteOSA system.<\/p>\n\n\n\n<p>Signifier will also fund further studies of the device to bolster the evidence of its treatment capabilities. It will continue to develop the eXciteOSA\u2019s accompanying digital management platforms for both patients and physicians.<\/p>\n\n\n\n<p>Roger Gunnarsson, the Managing Partner at Segulah Medical Acceleration, said in a statement that they are very thrilled about the prospects for eXciteOSA as a revolutionary daytime <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/obstructive-sleep-apnea-osa-market\">therapy to treat Obstructive sleep apnea (OSA)<\/a><\/strong>. With around 25% of the global adult population suffering from sleep-disordered breathing, they believe that eXciteOSA will become the first-line therapy for these patients.<\/p>\n\n\n\n<p>The eXciteOSA system centers on a handheld device, which is placed on the tongue for 20-minute sessions during the day. It emits low-intensity electrical impulses via four electrodes to trigger and strengthen the tongue and pharyngeal muscles.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Biogen-Ionis_experimental_drug_meets_primary_goal_in_Alzheimers_trial\"><\/span><strong>Biogen-Ionis\u2019 experimental drug meets primary goal in Alzheimer\u2019s trial<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Biogen and Ionis Pharmaceuticals have demonstrated that their experimental drug, BIIB080 (IONIS-MAPT), fulfilled the primary goal of safety and tolerability in the Phase Ib multiple ascending doses (MAD) clinical trials in mild <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\">Alzheimer\u2019s disease<\/a><\/strong> patients.<\/p>\n\n\n\n<p>An antisense treatment, BIIB080 potentially aims at microtubule-linked protein tau (MAPT) messenger RNA (mRNA) and impedes tau protein production. The placebo-controlled, two-part Phase Ib trial enrolled patients aged 50 to 74 years with confirmed amyloid positivity.<\/p>\n\n\n\n<p>The first part was a MAD study that comprised 46 subjects, while the second open-label long-term extension part is underway. Subjects were enrolled into four ascending dose arms and randomized in a 3:1 ratio to get various intrathecal (IT) bolus administrations of BIIB080 or placebo.<\/p>\n\n\n\n<p>Top-line data from the trial demonstrated that BIIB080 proffered a substantial time and dose-reliant decline in tau protein in cerebrospinal fluid (CSF) over a treatment period of three months and lasting decreases during the six months after treatment.<\/p>\n\n\n\n<p>Subjects receiving low, medium, and high BIIB080 doses every four weeks had a mean reduction of 30%, 40%, and 49%, respectively, in the total-tau concentration in CSF eight weeks after the last dose the drug. The group receiving the treatment every 12 weeks had a 42% mean reduction in the total-tau concentration.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"AbbVie_hits_go_on_USD_1_Billion_re-upped_Calico_deal_as_Googles_life_science_spin-out_continues_I-O_Neuropush\"><\/span><strong>AbbVie hits go on USD 1 Billion re-upped Calico deal as Google\u2019s life science spin-out continues I-O, Neuropush<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>AbbVie penned an early-stage deal seven years ago, with Google\/Alphabet\u2019s life sciences division Calico: the pair are penning a second extension for that collaboration.<\/p>\n\n\n\n<p>This deal first saw pen hit paperback in 2014 and focused on age-related diseases, comprising neurodegeneration and <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/brain-cancer-market\">cancer<\/a><\/strong>. Back in 2018, the pair inked their first extension to the collab, putting in an extra USD 1 billion to keep it going.<\/p>\n\n\n\n<p>Another USD 1 billion (divided into halves) goes into the pot, and another extension, bringing the deal another three years from 2022, now up to 2025. Under the terms, Calico is responsible for research and early development until that date and will push the collab projects into phase 2a through to the next decade.<\/p>\n\n\n\n<p>AbbVie, for its part, said it would continue to support Calico in its early R&amp;D efforts and, when those midstage tests are done, it has an option to manage late-stage development and the sales side.<\/p>\n\n\n\n<p>Since the deal got underway in 2014, in Calico\u2019s early days after being formed by Google, researchers have developed more than two dozen early-stage programs in <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/gene-therapy-in-oncology-innovation-to-commercialization-competitive-landscape\">oncology<\/a><\/strong> and neuroscience. They have also discovered the underlying biology of aging.<\/p>\n\n\n\n<p>Calico was by Alphabet and Calico CEO Arthur Levinson, Ph.D., who previously led Roche\u2019s Genentech as chairman and CEO. With an R&amp;D facility in the San Francisco Bay Area, the company remains relatively secretive, though this AbbVie deal has become one of its more public deals.<\/p>\n\n\n\n<p>Details on the pipeline are still very thin. However, it proffered a crumb of information for its lead immuno-oncology target, which is currently in phase 1 studies and includes two Protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, which act at multiple steps in the cancer immunity cycle.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Teneobio and its next-gen cancer work acquired by Amgen&nbsp; Amgen has penned a major new buyout deal to boost its oncology pipeline further. The biopharma is putting USD 900 million down upfront, with USD 1.6 billion in biobucks on the table to buy Teneobio and its suite of bispecific and multispecific antibody technologies focused on [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":13019,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[420,639],"industry":[17225],"therapeutic_areas":[17229,17506],"class_list":["post-13017","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-news","tag-pharma-news","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-sleep-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Amgen acquires Teneobio; Signifier scores $35M; Biogen&#039;s Alzheimer Drug<\/title>\n<meta name=\"description\" content=\"Amgen acquires Teneobio for $2.5B; Signifier scores $35M; Biogen-Ionis\u2019 drug meets a goal; AbbVie hits go on $1B re-upped Calico deal...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amgen acquires Teneobio; Signifier scores $35M; Biogen&#039;s Alzheimer Drug\" \/>\n<meta property=\"og:description\" content=\"Amgen acquires Teneobio for $2.5B; Signifier scores $35M; Biogen-Ionis\u2019 drug meets a goal; AbbVie hits go on $1B re-upped Calico deal...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-29T12:12:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-08-31T09:13:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/07\/29173220\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier.gif\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/gif\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Amgen acquires Teneobio; Signifier scores $35M; Biogen's Alzheimer Drug","description":"Amgen acquires Teneobio for $2.5B; Signifier scores $35M; Biogen-Ionis\u2019 drug meets a goal; AbbVie hits go on $1B re-upped Calico deal...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier","og_locale":"en_US","og_type":"article","og_title":"Amgen acquires Teneobio; Signifier scores $35M; Biogen's Alzheimer Drug","og_description":"Amgen acquires Teneobio for $2.5B; Signifier scores $35M; Biogen-Ionis\u2019 drug meets a goal; AbbVie hits go on $1B re-upped Calico deal...","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-07-29T12:12:36+00:00","article_modified_time":"2021-08-31T09:13:42+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/07\/29173220\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier.gif","type":"image\/gif"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier","name":"Amgen acquires Teneobio; Signifier scores $35M; Biogen's Alzheimer Drug","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/07\/29173220\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier.gif","datePublished":"2021-07-29T12:12:36+00:00","dateModified":"2021-08-31T09:13:42+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Amgen acquires Teneobio for $2.5B; Signifier scores $35M; Biogen-Ionis\u2019 drug meets a goal; AbbVie hits go on $1B re-upped Calico deal...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/07\/29173220\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier.gif","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/07\/29173220\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier.gif","width":772,"height":482,"caption":"recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/07\/29173220\/recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier-300x187.gif","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jul 29, 2021","modified":"Updated on Aug 31, 2021"},"absolute_dates_time":{"created":"Posted on Jul 29, 2021 5:42 pm","modified":"Updated on Aug 31, 2021 2:43 pm"},"featured_img_caption":"recent-pharma-happenings-for-amgen-teneobio-biogen-ionis-abbvie-signifier","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/13017","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=13017"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/13017\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/13019"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=13017"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=13017"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=13017"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=13017"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=13017"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}